We thank Bernard Freudenthal for his response to our previous Correspondence.1 We agree that use of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing among health-care workers (HCWs) solely to reduce absenteeism is inappropriate. Freudenthal correctly outlines the risks, posed by false-negative results, of advising potentially infectious HCWs to return to work. Moreover, staffing levels are currently far less problematic within UK health-care settings than during the peak of the pandemic.
HCW testing should aim to identify infectious cases and reduce nosocomial transmission of SARS-CoV-2: testing only self-reported symptomatic cases risks missing many infectious cases. For instance, HCWs might unwittingly attend work with mild or non-specific symptoms. Furthermore, although the relationship between RT-PCR cycle threshold (Ct) values and infectivity requires further elucidation, evidence suggests that Ct values among asymptomatic and symptomatic cases are similar.2 Crucially, viable virus has been isolated up to 6 days before symptom onset.3
Robust epidemiological studies help detail asymptomatic spread. Results have been heterogeneous; assumptions vary between studies which might be subject to recall bias, definitions of symptoms are inconsistent, and some studies do not account for the critical pre-symptomatic phase of infection. Nonetheless, most such studies find evidence of asymptomatic SARS-CoV-2 transmission.4
False-positive results can also limit HCW screening utility. They can be biological, with dead virus detected in non-infectious cases, and technical, where a test is positive in the absence of viral RNA. Regular screening risks identification of biological false positives; however, more research is required to understand the biology of persistent viral RNA shedding. Technical false positives might be reduced to manageable levels by testing in duplicate.5
We believe a symptom-agnostic testing approach for SARS-CoV-2 among HCWs is an effective measure of reducing viral transmission. This approach is advocated on a population level6 and might be particularly beneficial among HCWs given reports of hospitals acting as hotbeds of COVID-19.
Arguments against mass testing approaches previously have suggested a lack of resources might make this ineffective. However, UK daily testing capacity has increased tenfold since the publication of our Correspondence,1 while rapid point-of-care antigen tests facilitate early intervention to limit transmission.6
Screening for SARS-CoV-2 in asymptomatic HCWs could be a vital weapon in the fight against COVID-19 now and over the winter months. This will help the National Health Service to maintain the capacity to treat other diseases in the face of a second wave. We must act to prevent further virus spread, economic disruption, and unnecessary death.
© 2020 Bloomberg/Getty Images
Acknowledgments
CS reports grants from BMS, Ono-Pharmaceuticals, and Archer Dx (collaboration in minimal residual disease sequencing technologies), outside the submitted work; personal fees from Bristol Myers Squibb, Roche-Ventana, Ono Pharmaceutical, GlaxoSmithKline, Novartis, Celgene, Illumina, MSD, Sarah Canon Research Institute, Genentech, Bicycle Therapeutics, and Medicixi, outside the submitted work; personal fees and stock options from GRAIL and Achilles Therapeutics, outside the submitted work; and stock options from Epic Biosciences and Apogen Biotechnologies, outside the submitted work. All other authors declare no competing interests.
References
- 1.Black JRM, Bailey C, Przewrocka J, Dijkstra KK, Swanton C. COVID-19: the case for health-care worker screening to prevent hospital transmission. Lancet. 2020;395:1418–1420. doi: 10.1016/S0140-6736(20)30917-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Long Q-X, Tang X-J, Shi Q-L. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26:1200–1204. doi: 10.1038/s41591-020-0965-6. [DOI] [PubMed] [Google Scholar]
- 3.Arons MM, Hatfield KM, Reddy SC. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020;382:2081–2090. doi: 10.1056/NEJMoa2008457. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Buitrago-Garcia DC, Egli-Gany D, Counotte MJ. Asymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. medRxiv. 2020 doi: 10.1101/2020.04.25.20079103. published online July 28. (preprint) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Aitken J, Ambrose K, Barrell S. Scalable and robust SARS-CoV-2 testing in an academic center. Nat Biotechnol. 2020;38:927–931. doi: 10.1038/s41587-020-0588-y. [DOI] [PubMed] [Google Scholar]
- 6.Wain R, Sleat D. Taking the UK's testing strategy to the next level. Aug 17, 2020. https://institute.global/sites/default/files/articles/Taking-the-UK-s-Testing-Strategy-to-the-Next-Level.pdf